Targeting FGFR3 is a Useful Therapeutic Strategy for Rheumatoid Arthritis Treatment
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Rheumatoid arthritis (RA) is a systemic inflammatory disease in which TNF-α plays an important role. Fibroblast growth factor receptor 3 (FGFR3) is reportedly involved in RA by regulating the expression of inflammatory cytokines.
OBJECTIVE: This study examined the expression profile of FGFR3 in human synovial biopsy tissues and evaluated its gene-silencing effects on behaviors of synovial cells.
METHODS: Immunohistochemical staining was used to measure FGFR3 expression in human RA joint tissues. Cell proliferation, migration, and apoptosis assays were used to monitor behavioral changes in cultured synovial SW-982 cells with siRNA-mediated FGFR3 gene silencing. Immunofluorescent staining and western blotting were used to detect molecular changes in the FGFR3 gene-silenced cells.
RESULTS: FGFR3 up-regulation was noted in both cytoplasms and nuclei of synovial cells in human RA joints. FGFR3 siRNA delivery experiments corroborated that FGFR3 knockdown decreased proliferation and migration, and triggered apoptosis of synovial cells. The FGFR3 gene knockdown enhanced constitutive expression of epithelial marker E-cadherin and conversely suppressed expression of epithelial-mesenchymal transition (EMT) markers, including Snail, fibronectin, and vimentin. In addition, FGFR3 silencing significantly reduced the constitutive expressions of TNF-α, transcription factor NF-κΒ, and downstream COX-2 protein and collagenolytic enzyme MMP-9. MAPK inhibition markedly suppressed constitutive levels of NF-κΒ, COX-2, and MMP-9.
CONCLUSION: Genetic interference of FGFR3 could modulate the expression of inflammatory mediators and EMT markers in the synovial cells. Targeting the FGFR3/MAPK signal axis may be considered a useful therapeutic strategy to ameliorate the development of RA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Current molecular pharmacology - 17(2023), 1 vom: 20., Seite e18761429261684 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yu, Shan-Fu [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.11.2023 Date Revised 21.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/0118761429261684231002062505 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364738154 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364738154 | ||
| 003 | DE-627 | ||
| 005 | 20231226100044.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0118761429261684231002062505 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1215.xml |
| 035 | |a (DE-627)NLM364738154 | ||
| 035 | |a (NLM)37982287 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yu, Shan-Fu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeting FGFR3 is a Useful Therapeutic Strategy for Rheumatoid Arthritis Treatment |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.11.2023 | ||
| 500 | |a Date Revised 21.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: Rheumatoid arthritis (RA) is a systemic inflammatory disease in which TNF-α plays an important role. Fibroblast growth factor receptor 3 (FGFR3) is reportedly involved in RA by regulating the expression of inflammatory cytokines | ||
| 520 | |a OBJECTIVE: This study examined the expression profile of FGFR3 in human synovial biopsy tissues and evaluated its gene-silencing effects on behaviors of synovial cells | ||
| 520 | |a METHODS: Immunohistochemical staining was used to measure FGFR3 expression in human RA joint tissues. Cell proliferation, migration, and apoptosis assays were used to monitor behavioral changes in cultured synovial SW-982 cells with siRNA-mediated FGFR3 gene silencing. Immunofluorescent staining and western blotting were used to detect molecular changes in the FGFR3 gene-silenced cells | ||
| 520 | |a RESULTS: FGFR3 up-regulation was noted in both cytoplasms and nuclei of synovial cells in human RA joints. FGFR3 siRNA delivery experiments corroborated that FGFR3 knockdown decreased proliferation and migration, and triggered apoptosis of synovial cells. The FGFR3 gene knockdown enhanced constitutive expression of epithelial marker E-cadherin and conversely suppressed expression of epithelial-mesenchymal transition (EMT) markers, including Snail, fibronectin, and vimentin. In addition, FGFR3 silencing significantly reduced the constitutive expressions of TNF-α, transcription factor NF-κΒ, and downstream COX-2 protein and collagenolytic enzyme MMP-9. MAPK inhibition markedly suppressed constitutive levels of NF-κΒ, COX-2, and MMP-9 | ||
| 520 | |a CONCLUSION: Genetic interference of FGFR3 could modulate the expression of inflammatory mediators and EMT markers in the synovial cells. Targeting the FGFR3/MAPK signal axis may be considered a useful therapeutic strategy to ameliorate the development of RA | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Epithelial-mesenchymal transition | |
| 650 | 4 | |a FGFR3 | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 4 | |a Synoviocytes | |
| 650 | 4 | |a TNF-α. | |
| 650 | 7 | |a Matrix Metalloproteinase 9 |2 NLM | |
| 650 | 7 | |a EC 3.4.24.35 |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a Cyclooxygenase 2 |2 NLM | |
| 650 | 7 | |a EC 1.14.99.1 |2 NLM | |
| 650 | 7 | |a Receptor, Fibroblast Growth Factor, Type 3 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a RNA, Small Interfering |2 NLM | |
| 650 | 7 | |a FGFR3 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Cheng, Tien-Tsai |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Gong-Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Hsu, Chung-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Kao, Ying-Hsien |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Yueh-Hua |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current molecular pharmacology |d 2008 |g 17(2023), 1 vom: 20., Seite e18761429261684 |w (DE-627)NLM185149499 |x 1874-4702 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2023 |g number:1 |g day:20 |g pages:e18761429261684 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0118761429261684231002062505 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2023 |e 1 |b 20 |h e18761429261684 | ||